TNM8 Breast Cancer Calculator Downloads & RevenueTNM8 Breast Cancer Calculator · App Store
TNM8 Breast Cancer Calculator is #51 in Health & Fitness Paid in Brazil and charting in 3 of 30 countries we track.
Updated 9 Nov 2026 · rankings refresh through the day
DeveloperWesley Andrade
CategoryHealth & Fitness
Price10.99 USD
Released
Rating★ 3.4 (8)
Version3.3
Age rating12+
First seen by us
24 Sep 2026
24 Sep 2026Installs (est.)1k+ worldwide
TNM8 Breast Cancer Calculator update history & changes
Last change · 10 events since 19 Oct 2017Full timeline ↓📈Entered the top 100📈Entered the top 100 in 2 charts🆕First spotted by AppInsider🆕Released on the App Store
Full timeline · 9 events in the last 12 months
- 📈TNM8 Breast Cancer Calculator entered the top 100Top Paid · Health & Fitness · MX
- 📈TNM8 Breast Cancer Calculator entered the top 100 in 2 chartsTop Paid · Health & Fitness · AR · Top Paid · Health & Fitness · CA
- 📈TNM8 Breast Cancer Calculator charting in a new countryCanada
- 📈TNM8 Breast Cancer Calculator charting in a new countryArgentina
- 📈TNM8 Breast Cancer Calculator charting in a new countryColombia
- 📈TNM8 Breast Cancer Calculator entered the top 100Top Paid · Health & Fitness · US
- 📈TNM8 Breast Cancer Calculator charting in a new country in 2 chartsMexico · United States
- 🆕TNM8 Breast Cancer Calculator first spotted by AppInsider#50 in Top Paid · Health & Fitness · Brazil
- 🆕TNM8 Breast Cancer Calculator released on the App Store
Collected from the stores by AppInsider since we first spotted the app. Dates are when we saw each change.
Rating
3.4 ★
8 ratings
Measured
Best rank now
#51
Health & Fitness PaidMeasured
TNM8 Breast Cancer Calculator on the App Store
App details
App ID
1294700966
Publisher
Wesley Andrade
On the store since
Oct 2017
9 years on the store
Minimum OS
iOS 8.0+
iPhone 4s and later
Devices
iPhone · iPad · Watch
Content rating
12+
1 content note below
Languages
2
EN PT
Size
44 MB
Content notesInfrequent/Mild Medical/Treatment Information
TNM8 Breast Cancer Calculator downloads
Worldwide, per day, and installs to date. The band is open; the exact number is free with an account.
How this is calculated
Apple publishes no download counts. App Store downloads come from chart positions and daily rating growth per country, calibrated on Google Play install counts; lifetime installs from ratings worldwide × installs per rating. Confidence is the chance the real number is within half to double ours.
Where TNM8 Breast Cancer Calculator's downloads come from Modelled
Last 30 days: organic search, browsing the store, features and paid ads.
Active users
All platforms, worldwide. Free with an account.
Stickiness (DAU / MAU)
how many monthly users open it on a given day
How this is calculated
Monthly users come from lifetime installs across every store, fitted on monthly active user figures companies publish; daily users = monthly × the typical daily/monthly ratio for the category. Confidence is the chance the real number is within half to double ours.
Where it ranks now
Every top chart it appears in across 30 countries.
| Country | Charts | Rank |
|---|---|---|
| Brazil | Health & FitnessPaid | #51 |
 Mexico | Health & FitnessPaid | #131 |
 Colombia | Health & FitnessPaid | #139 |
Apps near TNM8 Breast Cancer Calculator on the chart
Health & Fitness Paid, around #51.
Ratings
App Store, worldwide.
Rating
3.4 ★
8 ratings
Measured
Ratings
8
Measured
Review momentum
ⓘ How we measure thisNew ratings a week
under 1
4-week average
Lifetime rating
3.8★
recent stars not readable yet: new ratings are a tiny share of the total
Review momentum
20/100
faster than 0% of Health & Fitness apps
Review momentum (0-100) blends how fast the app collects ratings compared with other apps in its category (60%), whether that pace is speeding up (25%) and what recent raters give it (15%; recent stars well below lifetime pull it down). Ratings counts are read daily. A jump usually means a launch, a feature, ads or a new review prompt.
About TNM8 Breast Cancer Calculator
Licensed by AJCC, TNM8 Breast Cancer Calculator is an updated, complete, intuitive, and user-friendly tool for Breast Cancer Staging based on the TNM 8th Edition - AJCC Cancer Staging Manual - Updated Breast Chapter with: Anatomic Stage, Clinical Prognostic Stage, and Pathological Prognostic Stage.
All data and definitions are based on the Updated Breast Chapter - AJCC Cancer Staging Manual 8th Edition, released on November 10th, 2017 that included the classic Anatomic Stage Group and the new and revolutionary Prognostic Stage Group (divided in Clinical Prognostic Stage and Pathological Prognostic Stage) with the incorporation of biomarker factors that predict more accurately cancer outcome for a more personalized and precise approach.
The prognostic factors included in the new TNM are: Tumor Grade (G), HER2, Estrogen Receptor (ER) and Progesterone Receptor (PR). Genomic Profiles were also incorporated as a prognostic factor for eligible cases (pT1-T2 N0 M0 HER2- and ER+) in the Pathological Prognostic Stage.
The Anatomic Stage is based solely on the anatomic extent of cancer as defined by the T, N, and M categories and should be used for all patients even if prognostic staging is possible.
The Clinical Prognostic Stage will be used to assign stage for all patients based on history, physical examination, imaging studies, and relevant biopsies. Clinical Prognostic Stage is determined by cT, cN, c/pM, G, HER2, ER, and PR. Genomic profile information is not included in Clinical Prognostic Stage.
The Pathological Prognostic Stage will be used to assign stage for patients who have the surgical resection as the initial treatment of their cancer before any systemic or radiation therapy. It includes all information used for clinical staging plus findings at surgery and pathological findings from surgical resection. Pathological Prognostic Stage is determined by pT, pN, c/pM, G, HER2, ER, and PR. Genomic profile information can be used for the Pathological Prognostic Stage (pT1-T2 N0, HER2- and ER+). Pathological Prognostic Stage does not apply to patients treated with chemotherapy, hormone therapy or radiation prior to surgical resection (neoadjuvant therapy).
This App provides the quantification of the category change of the Clinical Prognosis Stage (cPS) and also the Pathological Prognostic Stage (pPS) in relation to the Anatomic Stage (AS) expressed in the Staging Line with the symbol +1, +2, +3 in case of worsening in the Prognostic Staging or -1, -2, -3 in case of improvement in the Prognostic Staging. When no symbol is shown, it is because the AS and cPS or AS and pPS are identical.
This App has other function that shows Oncotype DX® / Genomic Profile field only in some setting when the genomic test is potentially indicated (pT1-T2 N0, HER2- and ER+).
This App is very useful for breast surgeons, surgical oncologists, medical oncologists, radiation oncologists, pathologists, radiologists, medical students, scientists, researchers, a
All data and definitions are based on the Updated Breast Chapter - AJCC Cancer Staging Manual 8th Edition, released on November 10th, 2017 that included the classic Anatomic Stage Group and the new and revolutionary Prognostic Stage Group (divided in Clinical Prognostic Stage and Pathological Prognostic Stage) with the incorporation of biomarker factors that predict more accurately cancer outcome for a more personalized and precise approach.
The prognostic factors included in the new TNM are: Tumor Grade (G), HER2, Estrogen Receptor (ER) and Progesterone Receptor (PR). Genomic Profiles were also incorporated as a prognostic factor for eligible cases (pT1-T2 N0 M0 HER2- and ER+) in the Pathological Prognostic Stage.
The Anatomic Stage is based solely on the anatomic extent of cancer as defined by the T, N, and M categories and should be used for all patients even if prognostic staging is possible.
The Clinical Prognostic Stage will be used to assign stage for all patients based on history, physical examination, imaging studies, and relevant biopsies. Clinical Prognostic Stage is determined by cT, cN, c/pM, G, HER2, ER, and PR. Genomic profile information is not included in Clinical Prognostic Stage.
The Pathological Prognostic Stage will be used to assign stage for patients who have the surgical resection as the initial treatment of their cancer before any systemic or radiation therapy. It includes all information used for clinical staging plus findings at surgery and pathological findings from surgical resection. Pathological Prognostic Stage is determined by pT, pN, c/pM, G, HER2, ER, and PR. Genomic profile information can be used for the Pathological Prognostic Stage (pT1-T2 N0, HER2- and ER+). Pathological Prognostic Stage does not apply to patients treated with chemotherapy, hormone therapy or radiation prior to surgical resection (neoadjuvant therapy).
This App provides the quantification of the category change of the Clinical Prognosis Stage (cPS) and also the Pathological Prognostic Stage (pPS) in relation to the Anatomic Stage (AS) expressed in the Staging Line with the symbol +1, +2, +3 in case of worsening in the Prognostic Staging or -1, -2, -3 in case of improvement in the Prognostic Staging. When no symbol is shown, it is because the AS and cPS or AS and pPS are identical.
This App has other function that shows Oncotype DX® / Genomic Profile field only in some setting when the genomic test is potentially indicated (pT1-T2 N0, HER2- and ER+).
This App is very useful for breast surgeons, surgical oncologists, medical oncologists, radiation oncologists, pathologists, radiologists, medical students, scientists, researchers, a
Latest updates
3.3
Melhoria de performance.